Source: Markets Insider

Kbp Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results PresentedPRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ('KBP ...

Read full article »
Kbp Biosciences's Competitors | Kbp Biosciences's News | Kbp Biosciences's Financials
Stay up-to-date with the latest news on Kbp Biosciences
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Brian P. McVeigh's photo - CEO of Kbp Biosciences

CEO

Brian P. McVeigh

CEO Approval Rating

75/100

Read more
Stay up-to-date with the latest news on Kbp Biosciences